Slide 1: Smarter anesthesia. Safer recoveries.
Smarter anesthesia. Safer recoveries. Pareto 2025 Philip Siberg
Slide 2: Curare: a deadly, paralyzing poison
A deadly, paralyzing poison Curare
Slide 3: Paralytic drugs are now standardized to facilitate safe surgery
Paralytic drugs are now standardized to facilitate safe surgery 100 million Paralyzes patients a year receive patient in ~45 paralytic drugs seconds 87% of patients ~40% leave the OR with are overdosed with with residual paralysis, at reversals, and 13% risk of complications underdosed1 ~$3 billion
Slide 4: The TetraGraph neuromuscular monitoring system
The TetraGraph neuromuscular monitoring system Algorithm-powered monitoring to secure precise dosing of paralytic drugs empowering clinicians with real-time signals to confidently determine when it's safe for patients to breathe on their own. >4,100 >750,000 >100 >40 TetraGraphs Patients Patents cov
Slide 5: Senzime pioneers a radical technology shift in monitoring patients under anesthesia
Senzime pioneers a radical technology shift enbling more precise monitoring of patients under anesthesia 51% 0.3% variability1 variability1 Traditional monitors Senzime’s TetraGraph based on AMG/KMG-technology monitor powered by EMG-technology monitors muscle movement, the indirect effects of muscle
Slide 6: EMG-based neuromuscular monitoring increases patient safety and reduces costs
EMG-based neuromuscular monitoring has shown to increase patient safety and reduce costs 0% complications related to post-operative residual block, when used with reversal drugs 70% reduction of the cost of reversal drugs as compared to not using quantitative monitoring. Thilen S. et al 2024: Anesth
Slide 7: Senzime's TetraGraph enables safe, effective, and less costly surgery
Senzime’s TetraGraph enables safe, effective, and less costly surgery Patient is deeply blocked to secure no movement during surgery – accurately monitored by the TetraGraph®
Slide 8: Making advanced monitoring intelligent and simple to perform
Making advanced monitoring intelligent and simple to perform Next-Generation TetraGraph® Adaptive 6th Generation Intelligence EMG Algorithm Aids in signal strength optimization Analyzes muscle function and automates workflows with at 4 times higher resolution, delivering TetraGraph® Adaptive PTC and
Slide 9: Supportive guidelines and practice recommendations
Supportive guidelines and practice recommendations 2025 Japanese Society of 2023 Anesthetists European Society (JSA) Anesthetists (ESA) 2021 guidelines EI Grupo Espanol 2020 de Rehabilitacion Canadian Multimodal 2019 Anesthesiology Society, Rev 1 Italian Society of Anesthesia, Analgesia, 2018 Reanim
Slide 10: Pediatric Guidelines for Neuromuscular Monitoring
And more guidelines to come… Addressing the most vulnerable patients: Pediatric Guidelines for Neuromuscular Monitoring
Slide 11: Backed by guidelines, strong clinical data, and a compelling hospital value proposition
Senzime - backed by guidelines, strong clinical data, and a compelling hospital value proposition 1 2 3 4 Objective Neuromuscular Electromyography (EMG)-based EMG-based Senzime's EMG-powered Monitoring (NMT) NMT monitoring NMT monitoring TetraGraph system is recommended by US and has proven to be si
Slide 12: Installed base of TetraGraph monitors keeps growing
Our installed base of TetraGraph monitors keeps growing, driving sales of disposable sensors Total delivered units of TetraGraph systems 727 TetraGraphs delivered 4,500 during Q2 4,000 3,500 3,000 2,500 2,000 1,500 1,000 500 0 Next-Generation Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2023 2024 2025 11
Slide 13: Installed base growth driving sales of disposable sensors
Our installed base of TetraGraph monitors keeps growing, driving sales of disposable sensors Shipped sensors (units) by month ‘22 - June ‘25 45,000 40,000 327,215 (153,365) TetraSens sensors sold 35,000 last 12 months 30,000 25,000 20,000 15,000 10,000 5,000 0 Jan Apr Jul Oct Jan Apr Jul Oct Jan Apr
Slide 14: First half of 2025: 90% sales growth in local currencies
First half of 2025: 90% sales growth in local currencies Net sales increased by 82% to 49.2 million SEK (27.0), Jan-June 2025 revenues (MSEK) 1 and 90% in local currencies. Sales boosted by Next-gen 50 TetraGraph and TetraSens 45 Deliveries of disposable sensors (units) grew 101% driven 40 2 by recu
Slide 15: One of the fastest growing medical device companies on Nasdaq Stockholm
We continue to be one of the fastest growing medical device companies on Nasdaq Stockholm Net sales rolling 12-months (kSEK) Net sales per quarter (kSEK) 90,000 30,000 80,000 25,000 70,000 60,000 20,000 50,000 15,000 40,000 30,000 10,000 20,000 5,000 10,000 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1
Slide 16: Global footprint with focus on US, Europe and key markets in Asia
Global footprint with focus on US, Europe and key markets in Asia Market opportunity: 64,000 Operating Rooms and 30 million procedures Market opportunity: 64,000 Operating Rooms and 30 million Market opportunity: procedures Licensing partners >30,000 Operating Rooms and 15 million procedures ▪ Direc
Slide 17: Product and market mix: Strong growth in all sectors
Product and market mix: Strong growth in all sectors Jan-June 2025 Currency Reported adjusted kSEK 2025 2024 Growth Growth Split sales per product group Split sales per region US 35 481 20 011 77% 86% Europe Instruments/other 16 307 8 959 82% 92% 14% Instru- Sensors 19 174 11 051 73% 80% ments Europ
Slide 18: Strong focus and commercial traction on US market
Strong focus and commercial traction on US market Sales in local USD currency in US market 101% sales growth Q2 vs. Q2 2024. Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Capital/Other Disposables
Slide 19: Selected key US TetraGraph installations in 2025
Selected key US TetraGraph installations in 2025 Pacific North-West Win of the world’s based hospital system leading hospital system Contract includes an initial order of 65 next- Installation of Next-Gen Northern MidWest based generation TetraGraph systems for TetraGraph monitors at multiple hospit
Slide 20: Outlicensed our technology in Japan
Outlicensed our technology in Japan Senzime has had a collaboration with Fukuda Denshi that dates back to 2016. Fukuda is one of the leaders in patient monitoring systems with a large installed base. By end of 2024, there were over 200 hospitals in Japan that had portable TetraGraphs installed in op
Slide 21: Integration and Connectivity to industry leaders
Integration and Connectivity to industry leaders TetraGraph Xcom and TetraHub – For seamless data integration Enables connectivity to a wide range of supported external hubs and monitors, ensuring the automatic transmission and display of quantitative TOF monitoring data. The Xcom/TetraHub cable als
Slide 22: Backed by a strong investor base
Backed by a strong investor base Largest shareholders June 30, 2025 Crafoord family and the Crafoord Foundation 25 196 551 16,1% Segulah Venture AB, Segulah AB, SMA 15 870 271 10,1% Fredrik Rapp 11 879 088 7,6% Fjärde AP-fonden 8 509 072 5,4% Avanza Pension 6 982 045 4,5% Unionen 6 080 000 3,9% Swed
Slide 23: Driving shareholder value by a recurring revenue-based business model
Driving shareholder value by a recurring revenue-based business model >16,000 50 kSEK 1,5 MSEK in hospitals 5 patients per week > per monitor and year > recurring revenue > = 20 bSEK in TAM Senzime’s mission is to be Usage rate target High compliance Revenue of typical Key markets per operating room
Slide 24: Outlook and goals
Outlook and goals Senzime’s mission is to be the undisputed global market leader in the field of EMG-based quantitative neuromuscular monitoring. 2025 outlook 2026 outlook Longer-term (5-7 y) Full year sales to reach a range of Guidance to reach revenues of Ambition to reach revenues SEK 110-140 mil
Slide 25: Leading the paradigm-shift of the decade in the OR
Leading the paradigm-shift of the decade in the OR Capno- Depth of EMG graphy anesthesia NMT 1980’s 1990’s 2000’s 2010’s 2020’s Pulse Oximetry & Cerebral AMG-based NMT Oximetry
Slide 26: Key take-aways
Key take-aways 1 2 3 HYPER GROWTH WE’RE WINNING BIG BUILDING BLOCKS IN PLACE • 90% growth in local currencies • Strong demand for Next-gen • Guidelines in place and driven by recurring sales of TetraGraph, and its ease-of-use more to come sensors as well as monitors expands market opportunity • Back
Slide 27: Safeguard every patient's journey, from anesthesia to recovery
So, join us on our mission to Safeguard every patient's journey, from anesthesia to recovery.